DE69927708D1 - Dosierungsformen, die poröse partikel enthalten - Google Patents

Dosierungsformen, die poröse partikel enthalten

Info

Publication number
DE69927708D1
DE69927708D1 DE69927708T DE69927708T DE69927708D1 DE 69927708 D1 DE69927708 D1 DE 69927708D1 DE 69927708 T DE69927708 T DE 69927708T DE 69927708 T DE69927708 T DE 69927708T DE 69927708 D1 DE69927708 D1 DE 69927708D1
Authority
DE
Germany
Prior art keywords
forms
active agent
pores
dosage forms
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69927708T
Other languages
English (en)
Other versions
DE69927708T2 (de
Inventor
Patrick Wong
David Edgren
Liang-Chang Dong
Crystal Pollock-Dove
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DE69927708D1 publication Critical patent/DE69927708D1/de
Publication of DE69927708T2 publication Critical patent/DE69927708T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
DE69927708T 1998-12-23 1999-12-23 Dosierungsformen, die poröse partikel enthalten Expired - Lifetime DE69927708T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11375098P 1998-12-23 1998-12-23
US11361598P 1998-12-23 1998-12-23
US11355998P 1998-12-23 1998-12-23
US113750P 1998-12-23
US113559P 1998-12-23
US113615P 1998-12-23
PCT/GB1999/004426 WO2000038655A1 (en) 1998-12-23 1999-12-23 Dosage forms comprising porous particles

Publications (2)

Publication Number Publication Date
DE69927708D1 true DE69927708D1 (de) 2006-02-23
DE69927708T2 DE69927708T2 (de) 2006-07-06

Family

ID=27381339

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927708T Expired - Lifetime DE69927708T2 (de) 1998-12-23 1999-12-23 Dosierungsformen, die poröse partikel enthalten

Country Status (12)

Country Link
EP (1) EP1140027B1 (de)
JP (1) JP2002533380A (de)
KR (1) KR100618234B1 (de)
AT (1) ATE306250T1 (de)
AU (1) AU1881600A (de)
CA (1) CA2355860C (de)
DE (1) DE69927708T2 (de)
DK (1) DK1140027T3 (de)
ES (1) ES2251251T3 (de)
HK (1) HK1040921B (de)
IL (2) IL143846A0 (de)
WO (1) WO2000038655A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
ES2392705T3 (es) * 2000-10-02 2012-12-13 Usv Ltd. Composiciones farmacéuticas de liberación sostenida que contienen metformina y método para su producción
US7083578B2 (en) * 2001-07-12 2006-08-01 Given Imaging Ltd. Device and method for examining a body lumen
KR20050043765A (ko) * 2001-11-06 2005-05-11 랜박시 래보러터리스 리미티드 방출 제어형 메트포르민 정제
AU2002359793B2 (en) * 2001-12-19 2007-06-14 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
ITMI20021392A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
CA2490412A1 (en) * 2002-06-28 2004-01-08 Alza Corporation Oral dosage from comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition
EP1771243A1 (de) * 2004-06-28 2007-04-11 H.Lundbeck A/S Poröser artikel zur zufuhr von chemischen substanzen
CN101001613B (zh) * 2004-06-28 2010-09-29 生命周期药物公司 作为液体制剂载体的多孔片剂
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
GB0420016D0 (en) * 2004-09-09 2004-10-13 Leuven K U Res & Dev Controlled release oral delivery system
CA2589079A1 (en) * 2004-11-03 2006-06-01 Equitech Corporation Nsaid compositions exhibiting clinical superiority
CA2611724C (en) 2005-06-10 2014-07-29 Pierre Fabre Medicament S.A. Stabilized milnacipran formulation
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
US8361515B2 (en) * 2005-12-31 2013-01-29 Tasly Pharmaceutical Group Co., Ltd. Extracts of Chenopodium ambrosioides L., the compositions comprising said extracts, the preparing process and application thereof
EP1973529B1 (de) * 2006-01-05 2011-05-25 LifeCycle Pharma A/S Zerfallende befüllbare tabletten
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
JPWO2009072334A1 (ja) * 2007-12-03 2011-04-21 富田製薬株式会社 製剤用核粒子
US9150419B2 (en) * 2008-05-10 2015-10-06 Us Synthetic Corporation Polycrystalline articles for reagent delivery
EP2135601A1 (de) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilisierung amorpher Arzneimittel über schwammähnliche Trägermatrizen
JP5560701B2 (ja) * 2008-12-26 2014-07-30 ライオン株式会社 ラニチジン含有医薬固形製剤及びラニチジン担持粒子の製造方法
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
CN102405042A (zh) 2009-05-04 2012-04-04 普西维达公司 多孔硅药物洗脱颗粒
US8798388B2 (en) 2009-12-03 2014-08-05 Qualcomm Incorporated Digital image combining to produce optical effects
WO2011079050A2 (en) 2009-12-23 2011-06-30 The Smart Pill Corporation Method of evaluating constipation using an ingestible capsule
WO2011120530A1 (en) * 2010-03-31 2011-10-06 Lifecycle Phama A/S Porous tablets as carriers for liquid formulations
WO2011156405A2 (en) * 2010-06-07 2011-12-15 Novadel Pharma Inc. Oral spray formulations and methods for administration of sildenafil
TWI615150B (zh) 2010-11-01 2018-02-21 匹史維迪亞美利堅公司 用於傳遞治療劑之生物可分解之以矽為主的裝置
WO2012166949A1 (en) 2011-05-31 2012-12-06 Regents Of The University Of Minnesota Silicate prodrugs and nanoparticles
BR112014013650A2 (pt) * 2011-12-05 2017-07-04 Suda Ltd "formulações de pulverização oral e seus usos"
CN104507309B (zh) 2012-03-19 2017-05-03 奇达拉治疗公司 用于棘白菌素类化合物的给药方案
KR20150048741A (ko) * 2012-07-27 2015-05-07 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도를 감소시키기 위한 약학적 조성물 및 이의 이용 방법
CA2904204A1 (en) * 2013-03-12 2014-10-09 Psivida Us, Inc. Drug delivery device comprising silicon-based carrier particles
JP2016512839A (ja) 2013-03-15 2016-05-09 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 治療物質の送達のための生体内分解性ケイ素系組成物
WO2015166472A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
RU2016147009A (ru) 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Композиции с пролонгированным высвобождением в виде суспензии
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10285908B2 (en) 2014-07-30 2019-05-14 Sun Pharmaceutical Industries Ltd Dual-chamber pack
MA41124A (fr) * 2014-12-05 2017-10-10 Sun Pharmaceutical Ind Ltd Compositions en suspension à libération prolongée à rétention gastrique
WO2016102944A1 (en) * 2014-12-23 2016-06-30 Lucideon Limited Porous particles
GB201502073D0 (en) 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
JP2021528452A (ja) * 2018-06-25 2021-10-21 タイタン ファーマシューティカルズ インコーポレイテッド インプラントとして使用するための装填可能な多孔質構造
US11389398B2 (en) 2019-05-14 2022-07-19 Clexio Biosciences Ltd. Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2155889B (en) * 1984-03-21 1988-03-02 Alza Corp Dispenser-capsule
GB8413191D0 (en) * 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
CA2038744C (en) * 1990-03-23 2002-01-08 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical composition containing slightly water-soluble drug
JP2700141B2 (ja) * 1993-09-17 1998-01-19 富士化学工業株式会社 リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤
US5800834A (en) * 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
DE69830997T2 (de) * 1997-03-03 2006-02-09 Sanofi-Aventis Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten
US5955086A (en) * 1998-06-18 1999-09-21 Biotics Research Corporation Oregano for the treatment of internal parasites and protozoa
US6376481B2 (en) * 1998-09-02 2002-04-23 Mcneil-Ppc, Inc. Sterol esters in tableted solid dosage forms

Also Published As

Publication number Publication date
DE69927708T2 (de) 2006-07-06
HK1040921A1 (en) 2002-06-28
IL143846A (en) 2007-03-08
EP1140027A1 (de) 2001-10-10
KR100618234B1 (ko) 2006-09-01
IL143846A0 (en) 2002-04-21
AU1881600A (en) 2000-07-31
DK1140027T3 (da) 2006-02-27
CA2355860A1 (en) 2000-07-06
KR20010093218A (ko) 2001-10-27
JP2002533380A (ja) 2002-10-08
HK1040921B (zh) 2005-12-30
CA2355860C (en) 2010-03-30
EP1140027B1 (de) 2005-10-12
ES2251251T3 (es) 2006-04-16
ATE306250T1 (de) 2005-10-15
WO2000038655A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
ATE306250T1 (de) Dosierungsformen, die poröse partikel enthalten
MY132999A (en) New formulation for inhalation
EP0973507A4 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
IL76257A (en) Sustained release tablets and method for their preparation
ATE190225T1 (de) Arzneiform zur abgabe von wirkstoffen an wunden
IS2563B (is) Ný blanda til innöndunar með lausþéttni sem er frá 0,28 til 0,38 g/ml, sem inniheldur búdesóníð
HUP9802498A2 (hu) Eljárás és berendezés hatóanyagoknak valamely szűrőanyagra történő felhordására
EE9900294A (et) Uus inhaleeritav formoterooli sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml
EP0494996A4 (en) Erodible macroporous hydrogel particles and preparation thereof
IL115869A0 (en) Implantable device for the administration of active substances to plants and a process for the production thereof
JPS5631425A (en) Deodorant agent
EE9900293A (et) Uus inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, selle valmistamise protsess ja kasutamine
WO1995013046A1 (en) Antiperspirants and method of applying antiperspirant using a shaped article
HUP0003566A2 (hu) Eljárás dózisforma előállítására, az előállított termék és alkalmazása
ATE44467T1 (de) Fibrinolytisches mittel und diffusionsfaktor enthaltende pharmazeutische zusammensetzung verwendbar zur behandlung des myokardinfarktes.
IL124538A (en) Transdermal delivery system for pharmaceutical compositions and a process for the preparation thereof
FR2070061A1 (en) Porous plastic articles for controlling the ovulation - cycle of animals
JPH0726321Y2 (ja) 電話機の除菌具
UA39677A (uk) Спосіб одержання покритої оболонкою таблетки корглікону
UA28103C2 (uk) Спосіб отримання таблетованої форми ортофену
JP2004315046A (ja) 医薬製剤用固形脱臭脱水剤
CA2212093A1 (en) Medicament form for the delivery of active substances to wounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition